| Composition | Olmesartan Medoxomil 40mg Amlodipine 5mg Hydrochlorothiazide 25mg |
|---|---|
| Dosage | TABLET |
| Packing Size | 10×10 |
| Packing | Alu-Alu |
OLMIVIN AMH 40/5/25 is a triple-combination antihypertensive medication designed for patients with resistant or uncontrolled hypertension. It combines Olmesartan Medoxomil 40 mg, Amlodipine 5 mg, and Hydrochlorothiazide 25 mg to provide potent and comprehensive blood pressure control, reducing the risk of heart attack, stroke, and kidney complications.
This combination targets three key mechanisms of blood pressure regulation, making it ideal for patients who require intensive therapy for optimal cardiovascular protection.
Each tablet contains:
Olmesartan Medoxomil 40 mg – Angiotensin II receptor blocker that relaxes blood vessels and lowers blood pressure.
Amlodipine 5 mg – Calcium channel blocker that relaxes vascular smooth muscles, improving blood flow.
Hydrochlorothiazide 25 mg – Thiazide diuretic that reduces fluid retention, decreasing blood volume and pressure.
(Excipients q.s., as per approved formulation.)
Tablet
Antihypertensive / Triple Combination Therapy
OLMIVIN AMH 40/5/25 Tablets are indicated for:
Management of hypertension (high blood pressure)
Patients requiring triple therapy for optimal blood pressure control
Prevention of cardiovascular events, such as heart attack and stroke
Reduction of hypertension-related kidney complications
Olmesartan Medoxomil blocks angiotensin II receptors, causing vasodilation and reducing aldosterone-mediated sodium retention.
Amlodipine inhibits calcium influx in vascular smooth muscles, lowering peripheral resistance.
Hydrochlorothiazide promotes excretion of sodium and water, reducing blood volume and pressure.
The triple combination provides synergistic antihypertensive effects, addressing vascular resistance, fluid retention, and hormonal regulation.
Recommended Dose: As prescribed by the physician, usually once daily
Route: Oral
Duration: Long-term therapy as advised by a healthcare provider
Note: Regular monitoring of blood pressure, electrolytes, and kidney function is recommended during therapy.
Provides potent and comprehensive blood pressure control
Reduces risk of heart attack, stroke, and kidney disease
Targets three different mechanisms for effective hypertension management
Convenient once-daily tablet improves adherence
Suitable for patients uncontrolled by monotherapy or dual therapy
OLMIVIN AMH 40/5/25 is generally well tolerated. Possible side effects include:
Dizziness or lightheadedness
Swelling of ankles or feet
Mild gastrointestinal discomfort
Electrolyte imbalances (rare)
Fatigue
Consult your physician if side effects persist or worsen.
Use with caution in renal or liver impairment
Avoid during pregnancy or lactation unless prescribed
Inform your doctor about other medications to prevent drug interactions
Regular monitoring of blood pressure, kidney function, and electrolytes is advised
Store below 25°C, in a dry place away from sunlight. Keep out of reach of children.
Brand Name: OLMIVIN AMH 40/5/25
Composition: Olmesartan Medoxomil 40 mg + Amlodipine 5 mg + Hydrochlorothiazide 25 mg
Dosage Form: Tablet
Therapeutic Class: Antihypertensive / Triple Combination Therapy
Manufacturer: [Insert Company Name]
Packaging: [Example: 10×10 Tablets / Strip]
Provides intensive triple-action blood pressure control
Reduces cardiovascular and renal risks associated with hypertension
Convenient once-daily dosing enhances compliance
Manufactured under strict GMP-certified quality standards
OLMIVIN AMH 40/5/25 (Olmesartan Medoxomil 40 mg + Amlodipine 5 mg + Hydrochlorothiazide 25 mg Tablets) delivers potent, triple-mechanism blood pressure management for patients with resistant or uncontrolled hypertension. By targeting vascular resistance, fluid retention, and hormonal regulation, it helps prevent cardiovascular and renal complications, supporting long-term heart health.
